On June 19, Institut Pasteur of Shanghai, CAS and Shanghai Institute of Biological Products signed a Memorandum of Cooperation in Shanghai.
IPS-CAS is competitive in scientific research dealing with all aspects of viral infectious diseases. Thanks to its networking capacity in particular in Asia and South East Asia, it has a unique capacity of study in infectious diseases, education and training, scientific exchange and transfer of know how in the domain of public health and education.
Shanghai Institute of Biological Products, part of the China National Biotec Corporation (CNBC), is one of the largest state-owned hi-tech enterprise engaged in research, development, manufacture and marketing of biological products in China. Manufacture and development of vaccines against viral diseases is one of the important focuses of SIBP.
The two Institutes will take complementary advantages to collaborate in basic research and industrialization projects with long-term vision. This cooperation will enable sharing of knowledge and talents, to develop vaccine and diagnosis reagents towards national and international marketing, and to contribute to improve the capacity of Shanghai Municipality and of China against infectious diseases. (IPS)